Lean Hogs (LH)

La vendita allo scoperto per Labcorp Holdings dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Labcorp Holdings. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Labcorp Holdings (NYSE:LH) Azioni, Report sulle vendite allo scoperto

Labcorp Holdings

Laboratory Corp

Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Labcorp Holdings Inc

LERER HIPPEAU ACQUISITION CORP

Linkhome Holdings Inc

Leo Holdings Corp II Ordinary Shares - Class A

Leo Holdings Corp II

LAZARD HEALTHCARE ACQUISITION CORP. I

Leo Holdings Corp II Warrants (07/01/2028)

Lucira Health Inc Ordinary Shares

LIC HSG FIN S/GDR 144A by Lic Housing Finance Ltd.

LIGHTHOUSE GLOGAL HLDGS by Lighthouse Global Holdings Inc.

Lighthouse Global Holdings Inc

LEHMAN BRO HLDC/T 6.00% M by Lehman Brothers Holdings, Inc.

Lehman Brothers Holdings Capital Trust V

LEADER HILL CORP by Leader Hill Corp.

LIONHEART IV CORP

LIFEHOUSE RETIREMENT PPTY by LifeHouse Retirement Properties, Inc.

LIONHEART III CORP

Lianhe Sowell International Group Ltd

LIGHTSTONE VALUE REIT by Lightstone Value Plus REIT Inc.

Lightstone Value Plus REIT I Inc

LIANHUA SUPERMKT HLDGS CO by Lianhua Supermarket Holdings Ltd.

Lianhua Supermarket Holdings Co Ltd

LIANHUA SPRMKT UNSP/ADR by Lianhua Supermarket Holdings Ltd.

L3Harris Technologies Inc

Lhyfe SA

Labcorp to serve as the exclusive NOWDiagnostics (NOWDx) distributor for clinical testing in the U.S., offering First to Know&#xAE; Syphilis Test nationwide
BURLINGTON, N.C., Oct 10, 2024 /PRNewswire/ -- Labcorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), a global leader of innovative and comprehensive laboratory services, announced today it has expanded its portfolio of sexually transmitted infection (STI) testing options to include the First to Know&#xAE; Syphilis Test, the first over-the-counter blood test granted market authorization by the U.S. Food &amp; Drug Administration (FDA) that can be performed by both physicians and patients.

Biotech

News

General

Laboratory Corporation Of America Holdings

Labcorp Expands STI Test Offerings, To Serve As The Exclusive NOWDiagnostics Distributor For Clinical Testing In The U.S., Offering First To Know Syphilis Test Nationwide

Labcorp Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lh#NYSE">LH</a>) or Labcorp benefits from the solid execution of its strategic priorities. Investment in targeted high-growth areas should drive the momentum. The company faces headwinds from macroeconomic uncertainties and growing foreign exchange issues. The stock carries a Zacks Rank #3 (Hold) currently.
<h2>Factors Driving LH Stock</h2>
LabCorp is well-placed for long-term success in Cell &amp; Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business. In June 2024, Labcorp Tissue Complete comprehensive genomic profiling (CGP) service was availed in Geneva and Shanghai to support global clinical trials. The integration of OmniSeq INSIGHT circulating tumor DNA expanded Labcorp&#39;s leadership in liquid biopsy comprehensive genomic profiling for solid tumors.
LabCorp&#39;s Biopharma business is benefiting from collaborations with leading pharmaceutical and biotechnology companies with whom it started to work on potential antivirals, treatments and vaccines. Revenue-wise, Biopharma&#39;s growth continues to be driven by strength in central laboratories, its largest part, which improved by 9% in the second quarter of 2024. The Early Development business is also recovering sequentially, led by reduced cancellations and booking improvement, and is expected to generate higher revenues in the second half of the year.
Labcorp has been focused on expanding its margins though the LaunchPad initiative. The company&#39;s 2024-2026 guidance includes a savings target range of $100 million-$125 million annually. The benefits will be driven by rationalizing the geographic location of facilities and talent, leveraging technological advancements and structural enhancements, integrating acquisitions and re-engineering the company&#39;s systems and processes. In the second quarter, the rise in operating income and margin was fueled by the strong demand and LaunchPad savings.
The stock has risen 11.1% in the past three months against the industry&#39;s 2.7% decline. With the company strategically expanding in the high-growth areas, as well as putting focus on cost saving initiatives, we expect the stock to continue its upward movement in the coming days.
<div class="chart_embed">
<h2>Labcorp Price</h2>
<img alt="Labcorp Price" src="https://staticx-tuner.zacks.com/images/charts/6d/1728307858.png" style="height:251px; width:545px" title="" />
Labcorp price | Labcorp Quote
</div>
<h2>Factors Weighing on LH Stock</h2>
Labcorp&#39;s operation is heavily dependent on the demand for diagnostic testing and drug development services from patients, physicians, hospitals, medical device companies and others. Volatilities in global economic conditions, including inflation and the risk of short or long-term recessions, could reduce the demand for these services, affecting the customers&#39; ability to pay and, consequently, the profitability of the company.
Added to this, the escalation of the present geopolitical situations in Ukraine and the Middle East can potentially decrease testing volumes, cause disruptions in the supply chain and services and increase the prices of offerings. In the second quarter, the cost of revenues went up by 4.7% year over year. SG&amp;A expenses increased 10.3%, mainly from higher personnel costs.
Labcorp&#39;s huge exposure in international markets makes it vulnerable to currency fluctuations. In 2023, the BLS segment derived nearly 58% of its revenues from overseas, while Dx also earned a modest portion in Canada and a relatively small amount in the rest of the world. An approximate 13.7% of the company&#39;s revenues were denominated in currencies other than the U.S. dollar in the first half of 2024. With the recent upward trend observed in the value of the U.S. dollar, further acceleration expected by analysts in this value will cause the company&#39;s revenues to face a tough situation overseas.&nbsp;In the second quarter, BLS and Dx revenue growth was partially offset by unfavorable foreign currency translation of 0.1%.
<h2>Key Picks</h2>
Some better-ranked stocks in the broader medical space are Intuitive Surgical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), TransMedics Group&nbsp;and Quest Diagnostics. While Intuitive Surgical and TransMedics currently sport a Zacks Rank #1 (Strong Buy) each, Quest Diagnostics carries a Zacks Rank #2 (Buy).
Intuitive Surgical&#39;s shares have surged 60.5% in the past year. Estimates for the company&#39;s earnings have moved 5.1% north to $1.65 per share for 2024 in the past 30 days.
ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.
Estimates for TransMedics&#39; 2024 EPS have moved up 125% to 27 cents in the past 30 days. Shares of the company have soared 135.2% in the past year compared with the industry&#39;s 14.9% growth.
TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 55.5% compared with the industry&#39;s 17.9% growth.
In the last reported quarter, BSX delivered an earnings surprise of 6.90%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.
<a href="https://www.zacks.com/stock/news/2347044/labcorp-stock-gains-from-biopharma-business-amid-fx-woe?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2347044">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Large Cap

Macro Economic Events

Guidance

Health Care

Offerings

Economics

Markets

Analyst Ratings

Trading Ideas

ISRG

Labcorp Stock Gains From Biopharma Business Amid FX Woe

Piper Sandler analyst David Westenberg initiates coverage on Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Neutral rating and announces Price Target of $235.

Price Target

Initiation

Piper Sandler Initiates Coverage On Labcorp Holdings with Neutral Rating, Announces Price Target of $235

Evercore ISI Group analyst Elizabeth Anderson maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a In-Line and lowers the price target from $250 to $240.

Evercore ISI Group Maintains In-Line on Labcorp Holdings, Lowers Price Target to $240

Jefferies analyst Brian Tanquilut maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and raises the price target from $245 to $265.

Jefferies Maintains Buy on Labcorp Holdings, Raises Price Target to $265

Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $257.67, with a high estimate of $282.00 and a low estimate of $215.00. Marking an increase of 5.65%, the current average surpasses the previous average price target of $243.89. 
<img src="https://www.benzinga.com/files/images/story/2024/1726833681_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Labcorp Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$282.00</td>
<td>$278.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$249.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$277.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$215.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$261.00</td>
<td>$258.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Labcorp Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Labcorp Holdings compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Labcorp Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Labcorp Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Labcorp Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind Labcorp Holdings</h2>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Holdings's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Labcorp Holdings showcased positive performance, achieving a revenue growth rate of 6.17% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.37%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.57%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Labcorp Holdings's ROA excels beyond industry benchmarks, reaching 1.24%. This signifies efficient management of assets and strong financial health.
Debt Management: Labcorp Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.75.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Labcorp Holdings

Baird analyst Eric Coldwell maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Outperform and raises the price target from $278 to $282.

Baird Maintains Outperform on Labcorp Holdings, Raises Price Target to $282

Ovia Health By Labcorp Announced The Expansion Of Its Women's Health Solutions To Include A Personalized, Comprehensive Postpartum Experience – A 12-month Program Designed To Help Women Manage Multiple Aspects Of The Postpartum Period

Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) (Labcorp) announced today that its wholly owned subsidiary, Laboratory Corporation of America Holdings (LCAH), has priced its offering of&nbsp;$2,000,000,000&nbsp;in senior notes (the Offering). The Offering consists of three tranches:&nbsp;$650,000,000&nbsp;aggregate principal amount of&nbsp;4.350%&nbsp;Senior Notes due 2030 (the 2030 Notes),&nbsp;$500,000,000&nbsp;aggregate principal amount of&nbsp;4.550%&nbsp;Senior Notes due 2032 (the 2032 Notes) and&nbsp;$850,000,000&nbsp;aggregate principal amount of&nbsp;4.800%&nbsp;Senior Notes due 2034 (the 2034 Notes and, together with the 2030 Notes and the 2032 Notes, the Notes).

Reported Earlier, Labcorp Prices $2B Senior Notes Offering Across Three Tranches With Maturities In 2030, 2032, And 2034

Cinven has reached an agreement to sell an indirect minority stake in SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, to strategic investor Labcorp. Labcorp is a global leader of innovative and comprehensive laboratory services headquartered in the United States. Labcorp will acquire the indirect minority stake through an intermediate holding company established to hold the investment with SYNLAB and will be represented on the holding company board along with Cinven and the other co-investors. The purchase price for this indirect minority stake of 15 percent was approximately €140 million.

Cinven To Sell 15% Stake In SYNLAB To Labcorp For €140M

LCAH expects to use the net proceeds of the Offering to redeem or repay indebtedness, which is expected to include&nbsp;$400.0 million&nbsp;of LCAH&#39;s outstanding&nbsp;2.30%&nbsp;Senior Notes due&nbsp;December 1, 2024&nbsp;and&nbsp;$1.0 billion&nbsp;of LCAH&#39;s outstanding&nbsp;3.60%&nbsp;Senior Notes due&nbsp;February 1, 2025. In addition, LCAH intends to use the net proceeds of the Offering to repay&nbsp;$350.0 million&nbsp;of borrowings under its revolving credit facility, and, to the extent not used for such purpose, for other general corporate purposes.

Reported Earlier, Labcorp Prices $2B In Senior Notes Offering Across Three Tranches Due 2030, 2032, And 2034

The acquisition includes&nbsp;BioReference Health's laboratory testing businesses focused on clinical diagnostics and reproductive and women's health in the United States outside of New York and New Jersey, including certain patient service centers (PSCs), customer contracts and operating assets, which currently generate approximately $100 million in annual revenue.

Labcorp Has Completed The Acquisition Of Select Assets Of And Opko Health's Bioreference Health For $237.5M

Labcorp Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) is reportedly collaborating with U.S. health regulators to determine whether it should scale up its mpox testing capabilities, following global concerns over a newly detected <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40554882/tonix-pharma-collaborates-with-worlds-largest-vaccine-manufacturer-for-mpox-vaccine" rel="noreferrer noopener">virus strain outside Africa</a>.
According to Marcia Eisenberg, the company's chief scientific officer, Labcorp currently processes around 500 mpox tests monthly but can ramp up to 25,000 if necessary, Reuters noted, citing an emailed statement.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40418733/mpox-vaccine-maker-bavarian-nordic-targets-broader-access-with-european-submission-for-imvanex-ad" rel="noreferrer noopener">Mpox Vaccine Maker Bavarian Nordic Targets Broader Access With European Submission For Imvanex Adolescent Use During WHO Emergency</a>.
The company recently received U.S. clearance for a home collection kit that doctors can order for patients aged 18 and older who are suspected of having mpox.
The clade Ib variant, previously found in the Democratic Republic of Congo and surrounding regions, has been detected in countries like Sweden and Thailand.
Labcorp, which produces a PCR test to detect mpox, is among several companies working on enhancing mpox testing infrastructure. Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) stated it is also monitoring global demand and exploring ways to leverage existing HIV testing infrastructure for mpox and other diseases in collaboration with African regulators.
Roche emphasized that its production capacities are designed to adapt to fluctuating global needs.
Other major diagnostics companies are also involved. Quest Diagnostics Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) offers mpox testing services, while Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) has developed the Alinity m test kit, which is authorized for emergency use in the U.S. as part of the ongoing response to the mpox outbreak.
Reuters also noted that Germany would donate 100,000 mpox vaccine doses from its military reserves to support efforts in containing the outbreak in Africa, a government spokesperson announced on Monday.
The government also plans to provide the World Health Organization with flexible funding to fight the virus and will back African partners through the GAVI vaccination alliance.
Germany currently holds around 117,000 doses of the Bavarian Nordic A/S (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BVNRY#OTC">BVNRY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BVNKF#OTC">BVNKF</a>)&nbsp;Jynneos vaccine, initially acquired for <a target="_blank" href="https://www.benzinga.com/news/24/08/40384390/mpox-declared-a-global-public-health-emergency-by-who-amid-rapid-international-spread" rel="noreferrer noopener">military stockpiling in 2022</a>.
Price Action: LH stock is up 0.29% at $231.56 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40558289/major-investor-says-galapagos-is-undervalued-plans-to-push-on-companys-performance-and-strategic-" target="_blank" rel="noreferrer noopener">Major Investor Says Galapagos Is ‘Undervalued,' Plans To Push On Company's ‘Performance' And ‘Strategic Opportunities'</a></li>
</ul>
Photo by NIAID via <a href="https://www.flickr.com/photos/niaid/52508743460/">Flickr</a>

Media

BVNKF

BVNRY

RHHBY

Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain

Labcorp Working With CDC To Monitor Mpox Outbreak; Currently Processing 500 Tests Monthly, Has Capacity For 25K/Month

Sandra D. van der Vaart, EVP at Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), executed a substantial insider sell on August 21, according to an SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000920148/000112760224022676//Archives/edgar/data/920148/000112760224022676/0001127602-24-022676-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, Vaart sold 2,000 shares of Labcorp Holdings. The total transaction value is $454,100.
Labcorp Holdings's shares are actively trading at $226.27, experiencing a up of 0.26% during Wednesday's morning session.
<h3>About Labcorp Holdings</h3>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Holdings: Financial Performance Dissected</h3>
Revenue Growth: Labcorp Holdings displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 6.17%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 28.76%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Labcorp Holdings's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 2.44.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.75, Labcorp Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Labcorp Holdings's P/E ratio of 41.95 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 1.54, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 16.96 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000920148">Check Out The Full List Of Labcorp Holdings's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Sandra D. van der Vaart Implements A Sell Strategy: Offloads $454K In Labcorp Holdings Stock

Disclosed on August 19, Glenn A Eisenberg, Chief Financial Officer at Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000920148/000112760224022401//Archives/edgar/data/920148/000112760224022401/0001127602-24-022401-index.htm">U.S. Securities and Exchange Commission</a> on Monday outlined that Eisenberg executed a sale of 15,000 shares of Labcorp Holdings with a total value of $3,359,824.
The latest update on Monday morning shows Labcorp Holdings shares down by 0.0%, trading at $227.5.
<h3>Discovering Labcorp Holdings: A Closer Look</h3>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Key Indicators: Labcorp Holdings's Financial Health</h3>
Revenue Growth: Over the 3 months period, Labcorp Holdings showcased positive performance, achieving a revenue growth rate of 6.17% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 28.76%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Labcorp Holdings's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 2.44.
</li>
</ul>
Debt Management: Labcorp Holdings's debt-to-equity ratio is below the industry average at 0.75, reflecting a lower dependency on debt financing and a more conservative financial approach.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 42.29, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 1.55, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 17.06, Labcorp Holdings presents an attractive value opportunity.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000920148">Check Out The Full List Of Labcorp Holdings's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Glenn A Eisenberg Implements A Sell Strategy: Offloads $3.36M In Labcorp Holdings Stock

Making a noteworthy insider sell on August 7, Lance Berberian, EVP at Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), is reported in the latest SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000920148/000112760224021768//Archives/edgar/data/920148/000112760224021768/0001127602-24-021768-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Berberian sold 12,093 shares of Labcorp Holdings. The total transaction amounted to $2,770,552. 
The latest market snapshot at Thursday morning reveals Labcorp Holdings shares down by 0.0%, trading at $219.36.
<h3>Get to Know Labcorp Holdings Better</h3>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Financial Insights: Labcorp Holdings</h3>
Revenue Growth: Labcorp Holdings's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 6.17%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company shows a low gross margin of 28.76%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Labcorp Holdings's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 2.44.
</li>
</ul>
Debt Management: Labcorp Holdings's debt-to-equity ratio is below the industry average at 0.75, reflecting a lower dependency on debt financing and a more conservative financial approach.
Exploring Valuation Metrics Landscape:
<ul>
<li>
Price to Earnings (P/E) Ratio: Labcorp Holdings's P/E ratio of 40.77 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 1.5, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 16.59, Labcorp Holdings could be considered undervalued.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000920148">Check Out The Full List Of Labcorp Holdings's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Labcorp Holdings EVP Trades Company's Stock

On August 7, a recent SEC filing unveiled that Lance Berberian, EVP at Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) made an insider sell.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000920148/000112760224021768//Archives/edgar/data/920148/000112760224021768/0001127602-24-021768-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Berberian sold 12,093 shares of Labcorp Holdings. The total transaction amounted to $2,770,552. 
As of Wednesday morning, Labcorp Holdings shares are down by 0.5%, currently priced at $224.73.
<h3>Discovering Labcorp Holdings: A Closer Look</h3>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Understanding the Numbers: Labcorp Holdings's Finances</h3>
Revenue Growth: Labcorp Holdings's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 6.17%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 28.76%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Labcorp Holdings's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 2.44.
</li>
</ul>
Debt Management: Labcorp Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.75.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 41.98 is lower than the industry average, implying a discounted valuation for Labcorp Holdings's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 1.54, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 16.97, Labcorp Holdings presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000920148">Check Out The Full List Of Labcorp Holdings's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Labcorp Holdings EVP Trades $2.77M In Company Stock

Throughout the last three months, 10 analysts have evaluated Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Labcorp Holdings, revealing an average target of $253.8, a high estimate of $277.00, and a low estimate of $215.00. Observing a 4.27% increase, the current average has risen from the previous average price target of $243.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1722884409_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Labcorp Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$249.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$277.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$215.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$261.00</td>
<td>$258.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$258.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$243.00</td>
<td>$261.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Labcorp Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Labcorp Holdings compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Labcorp Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Labcorp Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Labcorp Holdings analyst ratings.</a>
<h2>Discovering Labcorp Holdings: A Closer Look</h2>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Understanding the Numbers: Labcorp Holdings's Finances</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Labcorp Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.39% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.37%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Labcorp Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of 2.57%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Labcorp Holdings's ROA stands out, surpassing industry averages. With an impressive ROA of 1.24%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Labcorp Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.75.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Labcorp Holdings's Future

B of A Securities analyst Derik De Bruin maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and raises the price target from $240 to $260.

B of A Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $260

Labcorp subsidiary prices $2B notes offering

Jefferies analyst Brian Tanquilut maintained a Buy rating on Laboratory (LH – Research Report) today and set a price target of $265.00. The company...

Laboratory (LH) Receives a Buy from Jefferies

Stocks that are expected to benefit from lower fed funds rate and a softer labor market

Laboratory ( ($LH) ) has shared an announcement. Labcorp, a leading provider of laboratory services, will announce its third-quarter financial resu...

Labcorp Q3 2024 Earnings Release and Conference Call

Lazard U.S. Equity Concentrated Portfolio Q2 2024 Commentary

LabCorp started at neutral by Piper Sandler, price run up cited

WHO approves first mpox diagnostic test for emergency use

Laboratory Corporation of America declares $0.72 dividend

Labcorp Holdings declares $0.72 dividend

Laboratory ( ($LH) ) just unveiled an announcement. Labcorp Holdings Inc. has declared a quarterly cash dividend of $0.72 per share, payable on Dec...

Labcorp Announces Quarterly Cash Dividend for Shareholders

ADSK

APDN

AVGO

CBRE

CODX

CPAY

CRWD

CSCO

CTSH

EPAM

FFIV

GOOG

GOOGL

INTC

JKHY

KEYS

NTAP

NVDA

ORCL

ORLY

PANW

PAYC

RHHBF

TRMB

VRAX

WYNN

Press Releases

Labcorp Receives FDA De Novo Marketing Authorization for PGDx elio™ plasma focus Dx

Small Cap

Labcorp Finalizes Acquisition of Select Assets of Invitae

Labcorp to Speak at the Baird 2024 Global Healthcare Conference

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

LABCORP PRICES $650,000,000 IN 4.350% SENIOR NOTES DUE 2030, $500,000,000 IN 4.550% SENIOR NOTES DUE 2032 AND $850,000,000 IN 4.800% SENIOR NOTES DUE 2034

Ovia Health Expands Women's Health Offerings with Comprehensive Postpartum Experience

Labcorp to Announce Third Quarter Financial Results on October 24, 2024

Advantage Healthcare Holdings Appoints Dinak Nair as Chief Executive Officer

Dividends

Labcorp Declares Quarterly Dividend

Labcorp Expands Sexually Transmitted Infection (STI) Test Offerings with Rapid Syphilis Test

AHCO

NVTAQ

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Labcorp Holdings

Vendite allo scoperto

Labcorp Holdings (NYSE:LH) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO